Governance Natera, Inc.

NTRA

US6323071042

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2026 BST			5-day change	1st Jan Change
271.39 ^USD	+0.58%		+0.53%	+18.46%

07-17	Natera Highlights Impact of Final Local Coverage Determination for Prospera Portfolio	CI
07-13	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…

Executive Committee: Natera, Inc.

Manager

Positions heldSince

Stephen Chapman

47 year

Chief Executive Officer	01/01/2019
President	01/01/2019

Eric Evans

Chief Tech/Sci/R&D Officer

31/12/2019

Alexey Aleshin

Chief Tech/Sci/R&D Officer

31/12/2022

John Fesko

46 year

President

31/08/2023

Olesya Anisimova

Comptroller/Controller/Auditor

31/12/2021

Phil Grinnell

Sales & Marketing

31/12/2010

Michael Brophy

45 year

Director of Finance/CFO	31/01/2017
Investor Relations Contact	31/08/2015

Jerry Diffley

Compliance Officer

31/07/2017

Daniel Rabinowitz

56 year

General Counsel	30/06/2004
Corporate Secretary	30/06/2004

Rishi Kacker

Chief Tech/Sci/R&D Officer

31/12/2020

Composition of the Board of Directors: Natera, Inc.

Director

CommitteesSince

Matthew Rabinowitz

53 year

Chairman

30/04/2015

Roelof Botha

52 year

Audit Committee	15/06/2026
Compensation Committee	31/12/2010
Governance Committee	31/12/2006
Nominating Committee	31/12/2006

Roy Baynes

71 year

Governance Committee	30/11/2024
Nominating Committee	30/11/2024
Compensation Committee	30/11/2024

Gail Marcus

69 year

Audit Committee	23/01/2019
Governance Committee Chair	14/03/2017
Nominating Committee Chair	14/03/2017

Thomas Lynch

65 year

Governance Committee
Nominating Committee	26/10/2022
HR Committee	02/06/2026

Rowan Chapman

55 year

Audit Committee	14/08/2019
HR Committee Chair

Ruth Williams-Brinkley

74 year

Compensation Committee
HR Committee	01/03/2023

Herm Rosenman

78 year

HR Committee	31/01/2017
Audit Committee Chair

Eric Rubin

67 year

Governance Committee	25/03/2026
Nominating Committee	25/03/2026

Stephen Chapman

47 year

Director/Board Member

01/01/2019

Jonathan Sheena

53 year

Director/Board Member

31/12/2006

Latest Appointments: Natera, Inc.

07-06	Natera, Inc. Announces Resignation of Monica Bertagnolli as A Member of the Board and Any Committees of the Board, Effective July 1, 2026	CI
06-03	Natera Appoints Drs. Thomas Lynch and Eric Rubin to Board of Directors	CI
04-01	Natera, Inc. Appoints Eric Rubin to the Board and Member of Nominating, Corporate Governance and Compliance Committee, Effective March 26, 2026	CI
12/03/25	Natera, Inc. Appoints Monica Bertagnolli as A Member of the Board	CI
17/01/24	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Policymakers Warn Against Hopes of Large Rate Cuts	MT
18/09/23	Natera, Inc. Announces Senior Leadership Appointments	CI
23/02/23	Natera, Inc. Appoints Ruth E. Williams-Brinkley to Its Board of Directors, Effective March 2, 2023	CI

More news

Former Officers and Directors: Natera, Inc.

Insider

Positions held

SinceUntil

James Healy

Director/Board Member	31/10/2014	11/06/2025
Independent Dir/Board Member	31/10/2014	11/06/2025

Paul Greenland

Public Communications Contact	-	31/03/2023
Sales & Marketing	-	31/03/2023

Monica Bertagnolli

Director/Board Member	18/11/2020	11/08/2022
Independent Dir/Board Member	18/11/2020	11/08/2022
Director/Board Member	28/02/2025	30/06/2026
Independent Dir/Board Member	28/02/2025	30/06/2026

Todd Cozzens

Director/Board Member	31/12/2010	24/05/2022
Independent Dir/Board Member	31/12/2010	24/05/2022

Stas Budagov

Corporate Officer/Principal

31/12/2016

31/12/2021

Rahul Shukla

Corporate Officer/Principal

31/05/2020

30/11/2021

Ruben Gutierrez

General Counsel

30/04/2019

30/04/2021

Damon Silvestry

Human Resources Officer

31/03/2015

30/04/2020

Styrmir Sigurjonsson

Corporate Officer/Principal

31/12/2008

31/01/2020

Edward C. Driscoll

Director/Board Member	31/12/2006	15/05/2019
Independent Dir/Board Member	31/12/2006	15/05/2019

Cheng-Ho Lin

Chief Tech/Sci/R&D Officer

31/10/2015

31/03/2019

John D. Steuart

Director/Board Member	31/05/2007	23/01/2019
Independent Dir/Board Member	31/05/2007	23/01/2019

Robert Schueren

Chief Operating Officer

06/01/2019

Paul Billings

Chief Tech/Sci/R&D Officer

08/04/2018

Sundiep Phanse

Corporate Officer/Principal

31/12/2015

31/12/2017

Joshua Leichter

General Counsel

31/12/2017

Josh Sandifer

Human Resources Officer

31/12/2017

Michael C. Little

Chief Tech/Sci/R&D Officer	03/12/2015	-
Corporate Officer/Principal	-	31/12/2016

Diana de Walt

Human Resources Officer

31/12/2014

31/12/2016

Matthew M. Hill

Chief Tech/Sci/R&D Officer	31/12/2008	-
Corporate Officer/Principal	-	30/09/2016

Jonathan Wolin

Compliance Officer

30/06/2015

31/07/2016

Paco Cifuentes

Director/Board Member

31/07/2015

30/06/2016

Debbie Ledet

Corporate Officer/Principal

31/01/2014

29/02/2016

Asim Siddiqui

Corporate Officer/Principal

31/03/2013

31/05/2015

Susan J. Gross

Chief Tech/Sci/R&D Officer

19/12/2013

Darrin Crisitello

Sales & Marketing

31/12/2011

Barbara Pettersen

Chief Tech/Sci/R&D Officer

31/12/2006

Kate Starbrawa

Public Communications Contact

Michael Hromadik

Public Communications Contact

Nathan Hunkapiller

Chief Tech/Sci/R&D Officer

Gautam Kollu

Chief Tech/Sci/R&D Officer	-	-
Sales & Marketing	-	-

Eric Lindquist

Corporate Officer/Principal

Todd Sloan

Sales & Marketing

Chris Goulart

Corporate Officer/Principal

George M. Gemelos

Chief Tech/Sci/R&D Officer

David S. Johnson

Chief Operating Officer

Laura Zobkiw

Public Communications Contact

Age distribution of managers

Parity Men Women

Male	23
Female	4

Of which Executive Committee

Male	9
Female	1

Of which Directors

Male	10
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, womenâ€™s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the womenâ€™s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

Employees

6,138

Sector

Healthcare Facilities & Services

More about the company